OPDIVO®

(Nivolumab)

Documentation

Patented
Approved 2014
FDA Letter
FDA Label
Full Sequence

Brief Summary

Function Type: Antagonist
Target: CD279(PD-1)
Indication Category: Cancer

Approved Indications

Detailed Summary

Side Effects

References

Wikipedia
Drugs.com
FDA